Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975975 | 1.00 | ESR2 (0.42) | ESR2OPRL1FASNCYP2C9ESR1 | |
| SCHEMBL10043430 | 1.00 | ESR2 (0.42) | ESR2OPRL1FASNCYP2C9ESR1 | |
| SCHEMBL12975920 | 1.00 | ESR2 (0.42) | ESR2OPRL1FASNCYP2C9ESR1 | |
| SCHEMBL10043497 | 0.99 | ESR2 (0.40) | ESR2OPRL1FASNSCN9ADGAT1 | |
| SCHEMBL12975800 | 0.99 | ESR2 (0.40) | ESR2OPRL1FASNSCN9ADGAT1 | |
| SCHEMBL16546503 | 0.94 | ESR2 (0.37) | ESR2OPRL1FASNSCN9ADGAT1 | |
| SCHEMBL10043084 | 0.94 | ESR2 (0.37) | ESR2OPRL1FASNSCN9ADGAT1 | |
| SCHEMBL12975882 | 0.94 | ESR2 (0.37) | ESR2OPRL1FASNSCN9ADGAT1 | |
| SCHEMBL17900174 | 0.91 | ESR2 (0.40) | ESR2OPRL1FASNCYP2C9ESR1 | |
| SCHEMBL15630469 | 0.88 | ESR2 (0.48) | ESR2OPRL1FASNSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470199-B2 | Five-ring liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8470199-B2 | Five-ring liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| WO-2010146992-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | HTR3D, KIF23, CCND3 | ESR2 2435/4885OPRL1 2105/4885FASN 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.